Table 1 Patients` characteristics
| Characteristic | Number of patients absolute relative | |
|---|---|---|
| Sex | ||
| Female | 11 | 39.3% |
| Male | 17 | 60.7% |
| Karnofsky performance status (KPS) | ||
| 90–100% | 22 | 78.6% |
| 80% | 5 | 17.9% |
| 70% | 1 | 3.6% |
| BRAF Status | ||
| BRAF V600-E-Mutation | 14 | 50.0% |
| No BRAF V600-E-Mutation | 14 | 50.0% |
| Controlled extracranial disease | ||
| Yes | 10 | 35.7% |
| No | 18 | 64.3% |
| RPA class | ||
| 1 | 6 | 21.4% |
| 2 | 22 | 78.6% |
| 3 | 0 | 0% |
| Melanoma-molGPA | ||
| 0.5–1.0 | 2 | 7.1% |
| 1.5–2.0 | 11 | 39.3% |
| 2.5–3.0 | 11 | 39.3% |
| 3.5–4.0 | 4 | 14.3% |
| Number of SRS lesions per patient | ||
| 1 | 13 | 46.4% |
| 2 | 7 | 25.0% |
| 3 | 7 | 25.0% |
| 4 | 1 | 3.6% |
| Whole brain radiotherapy | ||
| Yes | 4 | 14.3% |
| Before first SRS | 1 | 3.6% |
| After first SRS | 3 | 10.7% |
| No | 24 | 85.7% |
| Targeted/ immunotherapy (TT/IT) | ||
| BRAFi (Dabrafenib/ Vemurafenib) MEKi (Trametinib) | 2 1 | 7.1% 3.6% |
| Anti-CTLA-4 (Ipilimumab) | 2 | 7.1% |
| Anti-PD1 (Nivolumab/Pembrolizumab) | 6 | 21.4% |
| BRAFi+MEKi (Dabrafenib-Trametinib/ Encorafenib-Binimetinib) | 3 | 10.7% |
| BRAFi+MEKi ➔ Anti-PD1 | 1 | 3.6% |
| Anti-PD1 + Anti-CTLA-4 (Nivolumab-Ipilimumab) | 7 | 25.0% |
| BRAFi+MEKi ➔Triple combination (Pembrolizumab-Dabrafenib-Trametinib) | 1 | 3.6% |
| none | 5 | 17.9% |
| Concurrent TT/IT | ||
| Yes | 20 | 71.4% |
| No | 8 | 28.6% |